Celltrion's STEQEYMA (ustekinumab-stba), now added to the Costco Member Prescription Program

Celltrion's adalimumab-aaty was previously added to the Costco Member Prescription Program in August 2024 [Press Release] On March 27, Celltrion announced that STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab) has been added to the Costco Member Prescription Program. "We're focused on improving affordability and access to a widely used, high-cost treatment for a variety of inflammatory conditions," said Francine Galante, Vice President of Market Access at Celltrion USA. "The addition of STEQEYMA to the Costco Member Prescription Program together with adalimumab-aaty will help us del

Handok’s Collaborator, Compass Therapeutics, Announces Positive Topline Results from Phase 2/3 of Tovecimig (HDB001A)

Handok plans to use COMPANION-002 clinical results for domestic approval of tovecimig (HDB001A) [Press Release] Handok's collaborator, Compass Therapeutics, announced positive topline results of COMPANION-002, a Phase 2/3 trial of tovecimig (HDB001A) in patients with metastatic or recurrent biliary tract cancer on April 1st (U.S. time). Handok and Compass Therapeutics have been collaborating on the development of tovecimig (HDB001A), an innovative bispecific antibody drug with high potential as a biliary tract cancer treatment. Compass Therapeutics has conducted the Phase 2/3 trial, COMPAN

ST PHARM Participates in DCAT Week 2025, Seeking Global Partnerships

Continuing participation following last year, aiming to attract global clients [Press Release] ST PHARM announced on March 21st that it participated in the Drug, Chemical & Associated Technologies (DCAT) Week 2025, held in New York City from March 17th to 20th. DCAT Week, which began in 1890 under the auspices of the New York Chamber of Commerce, is a premier event in the pharmaceutical and biotech sectors with over 150 years of tradition. The event is well-known for providing various forms of B2B partnering meetings, especially as it attracts high-level executives with de

Bioneer Participates in the American Academy of Dermatology (AAD)

Launches 'Cosmerna' Marketing in the North American Market [Press Release] Bioneer announced on the 12th that it participated for the first time in the American Academy of Dermatology (AAD) held in Orlando, Florida, USA, from March 7th to 11th. The company set up a booth for its hair loss cosmetic product "CosmeRNA" and conducted marketing activities for the brand during the event. The American Academy of Dermatology (AAD), established in 1939, is a globally renowned dermatology association with over 20,000 members from more than 100 countries, includin

SK bioscience and IVI Announce the 2025 Recipients of the ‘Park MahnHoon Award’ Four Honorees Recognized

Recipients selected for achievements in polio vaccine development and nonprofit initiatives to improve vaccination rates [Press Release] SK bioscience and the International Vaccine Institute (IVI) today announced the recipients of the 2025 Park MahnHoon Award, widely regarded as the "Nobel Prize of the vaccine industry." The honorees are Professor Pierre van Damme of the University of Antwerp and Dr. Ananda Sankar Bandyopadhyay of the Gates Foundation (joint recipients), as well as Ms. Luiza Helena Trajano, Chair of Grupo Mulheres do Brasil, and Ms. Svetha Janumpalli, CEO and Co-Founder of New Incentives (joint re

Medytox signs botulinum toxin distribution agreement worth USD 73 million with Blau Farmacêutica, from Brazil

Blau Farmacêutica S.A. (Brazil B3 BLAU3) will distribute Medytox’s products in the Brazilian market on an exclusive basis [Press Release] Medytox (CEO Hyun Ho Jung) announced on March 26th, 2024 that the biopharmaceutical company had entered into a distribution agreement (the "Agreement") with BLAU FARMACEUTICA S.A. (CEO Marcelo Hahn) for botulinum toxin at USD 73 million (based on minimum order quantity) for five years. Medytox will supply its botulinum toxin products (including Newlux) to Blau, which will distribute Medytox’s products in the territory of Brazil. The long-term Agreement came in the aftermath of Bl

Samsung Biologics recognized for leadership band in water security

[Press Release] Samsung Biologics announced on February 12 that it has received 'Leadership' status and an A- rating for water security from the Carbon Disclosures Project (CDP), underscoring the company’s efficient water resources management. The company participated in the category for the first time. CDP is a non-profit organization that evaluates the corporate environmental transparency and performance of over 24,800 companies listed worldwide. The rating recognizes Samsung Biologics’ effort

HK inno.N’s K-CAB wins a landmark victory in the second-instance trial for its substance patent

[Press Release] HK inno.N, announced on Thursday (6th of February) that the company won the second-instance trial following its win in the first-instance trial related to the compound (substance) patent for its new acid-related disease treatment ‘K-CAB Tablet (K-CAB).’ Following the favorable ruling by the Intellectual Property Trial and Appeal Board (IPTAB), Intellectual Property High Court also ruled in favor of HK inno.N, the originator company, which indicates that K-CAB is granted patent pr

Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States

Pictured from left: McK Kevin Cloutier (Vice President of Sales & Business Development, McKesson Pharmacy Automation, USA), Yves Blanchette (Vice President of Technology Solutions, McKesson Canada), Hanmi Pharmaceutical Overseas Sales Team Leader Lee Ji-hyun, and McK Steve Dennison (Vice President and General Manager, McKesson Canada Automation). [Press Release] Hanmi Pharmaceutical's Global Business Headquarters Overseas Sales Team is making significant strides in penetrating the Canadian and U

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

[Press Release] The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant attention in the field of immunotherapy. On November 25, Hanmi announced that it presented the research and clinical progress of BH3120 in a poster session at the Society for Immunotherapy of Cancer (SITC) conference, held in Houston, USA, from